Holen Sie sich die Stockscreener-App
267.66
3.29%
8.2714
Schlusskurs vom Vortag:
$259.39
Offen:
$259.09
24-Stunden-Volumen:
366.63K
Relative Volume:
0.41
Marktkapitalisierung:
$32.98B
Einnahmen:
$2.25B
Nettoeinkommen (Verlust:
$-278.16M
KGV:
-123.35
EPS:
-2.17
Netto-Cashflow:
$-42.59M
1W Leistung:
+5.13%
1M Leistung:
+13.66%
6M Leistung:
+1.00%
1J Leistung:
+75.89%
1-Tages-Spanne:
$257.23
$271.32
1-Wochen-Bereich:
$247.71
$271.32
52-Wochen-Spanne:
$144.73
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
266.92 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.30 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.90 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.93 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
253.06 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference | ALNY Stock News - GuruFocus
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - Eagle-Tribune
Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Target Price Raised by UBS | ALNY Stock News - GuruFocus
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - Yahoo Finance
UBS Boosts Alnylam (ALNY) Price Target Amid Promising Early Launch Trends | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Ch - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating - marketscreener.com
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight - GuruFocus
Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo
Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlig - GuruFocus
Alnylam: Q1 Earnings Snapshot - MySA
Alnylam Earnings: Launch of Amvuttra for ATTR-CM Underway; Fair Value Up to $245 From $223 - Morningstar
Narrow-Moat Alnylam's Strong Patient Uptake Drives Growth; Diverse Pipeline Makes Progress - Morningstar
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia - Seeking Alpha
Alnylam Pharmaceuticals Reports Strong Start to 2025 - TipRanks
Alnylam Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Alnylam (ALNY): Price Target Raised Amid Promising Amvuttra Laun - GuruFocus
Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2025 Growth - GuruFocus
Alnylam Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Alnylam Q1 2025 beats EPS forecast, stock drops - Investing.com India
Alnylam Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Alnylam Q1 2025 slides: 28% revenue growth as AMVUTTRA drives TTR franchise expansion - Investing.com
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises - marketscreener.com
ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet - simplywall.st
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe - simplywall.st
Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha
European Regulators Endorse Breakthrough ATTR-CM Treatment as Alnylam Hits All 10 Trial Endpoints - Stock Titan
Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency - marketscreener.com
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Tr - GuruFocus
Alnylam (ALNY) Secures EMA Committee Support for Expanded Use of Vutrisiran | ALNY Stock News - GuruFocus
Alnylam’s vutrisiran gets positive CHMP opinion for ATTR-CM - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Alnylam (ALNY) Gains Positive CHMP Opinion for Amvuttra Label Ex - GuruFocus
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 24 '25 |
Sale |
300.00 |
5,445 |
1,633,500 |
20,221 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 21 '25 |
Sale |
285.00 |
4,321 |
1,231,485 |
20,221 |
| PYOTT DAVID E I | Director |
Mar 24 '25 |
Option Exercise |
88.95 |
7,440 |
661,788 |
7,576 |
| PYOTT DAVID E I | Director |
Mar 24 '25 |
Sale |
299.00 |
7,440 |
2,224,560 |
136 |
0.99%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):